clinical trial · NCT06933056
Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
University of Michigan·early phase1·recruiting·n = 20
Platelet Function and Reactivity TestsSotagliflozin (SOTA) followed by 3 drugs in a random orderAspirin followed by 3 drugs in a random orderClopidogrel followed by 3 drugs in a random orderEliquis followed by 3 drugs in a random order
brief summary
This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.
started
Sep 2, 2025
primary completion
Sep 1, 2026
completion
Sep 1, 2026
last updated
Sep 15, 2025
official title
Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs: an Interventional Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol